This website uses cookies for usage measurement and traffic analysis purposes.
By clicking the "Agree" button or continuing to browse this site, you consent to the use of cookies.
For more details, please refer to the Privacy Policy
(opens in a new window).
Dr. Kobayashi graduated with his MD from Mie University in 2008 and completed residency at Iizuka Hospital. He worked as a thoracic surgeon at Aichi Cancer Center (2010-2014) and Kindai University (2014-2018). He completed his PhD in 2017 with projects on EGFR-mutant lung cancer. He joined Pasi Janne lab at Dana-Farber Cancer Institute as a research fellow in 2018 and investigated projects on drug resistance in EGFR mutant lung cancer and novel RAS-targeted therapy. He moved to Division of Molecular Pathology at National Cancer Center Research Institute as a scientist in 2021 and continues basic and translational research for the treatment of patients with cancer.
Research on drug resistance and novel theapy by uncovering the underlying mechanisms of cancer biology
Division of Molecular Pathology
Board certified general thoracic surgeon and Councilor (The Japanese Association for Chest Surgery), Board certified surgeon (Japan Surgical society), Councilor (Nucleic Acids Therapeutics Society of Japan)
| 2021.1-present | Scientist, Division of Molecular Pathology at National Cancer Center Research Institute |
| 2018.4-2020.12 | Research Fellow, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School |
| 2014.4-2018.3 | Assistant professor, Department of Thoracic Surgery, Kindai University Faculty of Medicine |
| 2010.4-2014.3 | Resident/ Senior resident, Department of Thoracic Surgery, Aichi Cancer Center |
| 2008.4-2010.3 | Resident, Iizuka hospital |
